Elevated levels of utilization, particularly in MA, has been an ongoing trend for the large, national firms, who have seen higher costs in this space for more than a year
In AWARD-10 [31], a 24-week, randomized, double-blind, placebo-controlled trial evaluating once-weekly dulaglutide (administered at either 1.5 or 0.75 mg) as add-on therapy to SGLT2is in a total of 424 patients with inadequately controlled T2DM, only one episode of severe hypoglycemia was reported throughout the study, in a patient treated with dulaglutide 0.75 mg, confirming the very low incidence of serious hypoglycemia with GLP-1RAs in combination with SGLT2is [31]
U-500 syringes have markings where 1 unit on the barrel equals 5 units of insulin, which would deliver 5x the intended semaglutide dose
Q: How do I know which treatment is right for me